772 results on '"Bomback, Andrew"'
Search Results
152. Chapter 49 - Lupus Nephritis
153. LUPUS NEPHRITIS: Ancestry, genetic risk and health disparities
154. GLOMERULAR DISEASE: ANCA-associated GN—to PLEX or not to PLEX?
155. The Association between Parathyroid Hormone Levels and Hemoglobin in Diabetic and Nondiabetic Participants in the National Kidney Foundationʼs Kidney Early Evaluation Program
156. Increased prevalence of acute interstitial nephritis: more disease or simply more detection?
157. The Association of Parathyroid Hormone with ESRD and Pre-ESRD Mortality in the Kidney Early Evaluation Program
158. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN
159. Renal-limited ‘lupus-like’ nephritis
160. A simple prediction score for kidney disease in the Korean population
161. Mineralocorticoid Receptor-Associated Hypertension and Target Organ Damage: Clinical Relevance for Resistant Hypertension in End Stage Renal Disease
162. Patient perspectives and involvement in precision medicine research
163. Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program
164. Proposal for a more practical classification of antineutrophil cytoplasmic antibody-associated vasculitis
165. Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study
166. Postmortem Kidney Pathology Findings in Patients with COVID-19
167. Persistent Disease Activity in Patients With Long-Standing Glomerular Disease
168. How COVID-19 Has Changed the Management of Glomerular Diseases
169. Ask and It Shall Be Given
170. Pilot Study of Return of Genetic Results to Patients in Adult Nephrology
171. Updates on the Treatment of Lupus Nephritis
172. Gestational Diabetes Mellitus Alone in the Absence of Subsequent Diabetes Is Associated With Microalbuminuria: Results from the Kidney Early Evaluation Program (KEEP)
173. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy
174. Contributors
175. Development and Validation of a Patient Self-assessment Score for Diabetes Risk
176. Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience
177. Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?
178. A Simple Algorithm to Predict Incident Kidney Disease
179. The incidence and implications of aldosterone breakthrough
180. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: a reply
181. Errands
182. Becoming a Physician: The Physical Exam and the Sense of Smell
183. Use of ofatumumab and eplerenone in post‐transplant recurrence of FSGS.
184. An Update on Therapies for Proliferative Lupus Nephritis: How Certain Can We Be About the Evidence?
185. Efficacy and Safety of Iptacopan in Patients with C3 Glomerulopathy: 12-Month Results from the Phase 3 APPEAR-C3G Study
186. Value of Genetic Testing in a Glomerular Disease Center
187. AKI in the Kidney Precision Medicine Project: Acute Tubular Injury vs. Acute Interstitial Nephritis
188. Pegcetacoplan for Post-transplant Recurrent C3 Glomerulopathy (C3G) or Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) in NOBLE: 52-Week Patient Evolution
189. VALIANT: A Randomized, Multicenter, Double-Blind, Placebo (PBO)-Controlled, Phase 3 Trial of Pegcetacoplan for Patients with Native or Post-transplant Recurrent Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
190. MAJESTY: A Phase 3, Randomized, Open-Label, Active Comparator-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy
191. CureGN-Diabetes Study: Rationale, Design, and Methods of a Prospective Observational Study of Glomerular Disease Patients with Diabetes
192. 25 - Systemic Lupus Erythematosus and the Kidney
193. Glomerular Diseases in Patients with Diabetes Mellitus: An Underappreciated Epidemic
194. The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis
195. Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP)
196. Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience
197. Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis
198. In Search of C3G Tissue Biomarkers
199. Health-related quality of life in glomerular disease
200. Rituximab for Anti–Glomerular Basement Membrane Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.